11Jan2023 Avillion announces US approval of AstraZeneca’s Airsupra (PT027) as new rescue treatment for asthma
31May2022 US FDA accepts New Drug Application filed by Avillion for AstraZeneca’s PT027 for the as-needed treatment or prevention of symptoms in asthma patients
16May2022 Avillion announces publication of positive full results from MANDALA Phase III trial of AstraZeneca’s PT027 in asthma patients in the New England Journal of Medicine
09Sep2021 Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca’s PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
10May2021 JPM ranked Avillion #61 in the top 200 Female-Powered Private Businesses in the UK – April 2021
23Apr2021 Avillion’s positive Phase 2 trial of tri-specific Nanobody® sonelokimab (M1095) in chronic psoriasis published in The Lancet
29Oct2020 Positive results from Avillion’s Phase 2 trial of sonelokimab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual